[{"id":"ce6acbdf-d0c9-46e4-a247-444e713619ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413095","created_at":"2024-05-18T04:21:47.057Z","updated_at":"2025-02-25T16:02:48.188Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","source_id_and_acronym":"NCT06413095","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • IFNG • CD163 • GZMB","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD163 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 06/22/2023","study_completion_date":" 06/22/2023","last_update_posted":"2024-05-14"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"569b7a3c-398d-4a63-9bd9-f84589797a41","acronym":"","url":"https://clinicaltrials.gov/study/NCT03918278","created_at":"2021-03-22T14:52:14.407Z","updated_at":"2024-07-02T16:35:15.378Z","phase":"Phase 1","brief_title":"A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)","source_id_and_acronym":"NCT03918278","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1 • MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["EGFR • ALK • ROS1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 02/19/2025","primary_completion_date":" 02/19/2025","study_txt":" Completion: 02/19/2025","study_completion_date":" 02/19/2025","last_update_posted":"2024-03-11"},{"id":"a773610b-43c7-4cf0-b3a9-805cd9684517","acronym":"KEYMAKER-U01B","url":"https://clinicaltrials.gov/study/NCT04165083","created_at":"2021-01-18T20:19:29.647Z","updated_at":"2024-07-02T16:35:19.534Z","phase":"Phase 2","brief_title":"KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)","source_id_and_acronym":"NCT04165083 - KEYMAKER-U01B","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 09/17/2025","primary_completion_date":" 09/17/2025","study_txt":" Completion: 09/17/2025","study_completion_date":" 09/17/2025","last_update_posted":"2024-02-13"}]